The Department of Health and Human Services has partnered with Genentech to develop medicines that can help address national health security requirements under an “other transaction” agreement.
HHS’ Biomedical Advanced Research and Development Authority and the biotechnology firm agreed to share costs of developing a drug portfolio for potential commercialization in compliance with the Pandemic and All Hazards Preparedness Act of 2006, the department said Monday.
The agency will provide $43M to support a five-year study on the efficacy of baloxavir marboxil to treat patients hospitalized for severe seasonal or pandemic influenza viruses.
BARDA will also allocate $19M to help Genentech further develop alteplase as a treatment for cast formation or acute lung injuries that resulted from inhaling sulfur mustard gas.
The partnership seeks to advance the drug known under the Activase brand and used to treat stroke, heart attack and pulmonary embolism.
The agreement represents BARDA’s eight OTA.